Clinical trial
A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
NCT02086045 is registered in ClinicalTrials.gov with Elixir Medical Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
- Lead sponsor
- Elixir Medical Corporation
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- May 15, 2017
- Enrollment
- 126 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.